Article

Episcleral tattooing can cause lumpy conjunctivae

A patient’s red, lumpy conjunctivae demonstrate the risk of episcleral tattooing, according to physicians at the Ophthalmology Department of Maidstone Hospital in Maidstone, Kent, United Kingdom.

A patient’s red, lumpy conjunctivae demonstrate the risk of episcleral tattooing, according to physicians at the Ophthalmology Department of Maidstone Hospital in Maidstone, Kent, United Kingdom.

The case is the first reported complication from episcleral tattooing in the medical literature, write James Brodie and two colleagues at the hospital in an August 8 article for BMC Ophthalmology.

“We feel that the potential risks of the procedure should be communicated more widely to those body modification practitioners undertaking it,” they report.

Nutritional supplements may fight diabetic retinopathy

Reports of episcleral tattooing date back to at least 2007, the researchers said. The number of body modification procedures is growing and including more extreme practices. But so far only a small number of people have opted for episcleral tattooing. With this in mind, when a 43-year-old Caucasian man came to the hospital 7 weeks after receiving injections under the conjunctiva at 3 sites in each eye, it really caught their attention. The tattoo pigments consisted of two dermal tattoo dyes: C.I Pigment Red 210 and C.I. Pigment Blue 15.

The man complained that conjunctival lumps had not subsided. On slit lamp examination, the physicians found a distinct area of swelling at each of the 6 injection sites. He reported no discomfort or visual symptoms; his visual acuity was 6/4 in both eyes. Fundal examination and intraocular pressure measurements were also normal. And other than the persistent lumpy appearance, the physicians found no other gross abnormalities. Six months later, the only change they could find was a slight fading of the dye. But they planned to keep a watch on the patient for further complications such as granulomatous inflammation.

Next: Understanding the risks

 

Understanding the risks

Mass media have reported headaches, severe photophobia, persistent foreign body sensation, and migration of ink staining to nearby tissues, the researchers say.

The theoretical risks include globe penetration, traumatic cataract, retinal detachment and endophthalmitis, especially when carried out by a user not trained in ophthalmology without the use of a surgical microscope.

Granuloma could eventually lead to sclera thinning or malignancy.

Finally, ordinary skin tattoo can cause uveitis, so putting the eye under the conjunctiva may increase this risk, and raises the possibility of blindness, the researchers speculate. So they warn practitioners to be on the lookout for more tattooed scleras.

“This practice could result in more serious presentations to acute eye services in the coming years,” they reported.

In case you missed it:

OD-performed surgery unaceptable, dangerous

Top 10 ophthalmic advancements over past 20 years

Did you know these 7 men were ophthalmologists?

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.